KCS Wealth Advisory’s GSK GSK Stock Holding History

KCS Wealth Advisory’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$775K	Buy	21,391 +314	+1%	+$11.1K	0.33%	74
2023 Q2	$751K	Buy	21,077 +862	+4%	+$30.9K	0.26%	88
2023 Q1	$719K	Buy	20,215 +2,004	+11%	+$70.1K	0.27%	88
2022 Q4	$640K	Sell	18,211 -5,795	-24%	-$193K	0.27%	87
2022 Q3	$706K	Buy	24,006 +1,799	+8%	+$68.2K	0.33%	85
2022 Q2	$1.21M	Buy	22,207 +270	+1%	+$14.9K	0.54%	67
2022 Q1	$1.19M	Buy	21,937 +1,032	+5%	+$56.1K	0.55%	65
2021 Q4	$1.15M	Buy	20,905 +1,115	+6%	+$58K	0.46%	73
2021 Q3	$945K	Buy	19,790 +133	+0.7%	+$6.68K	0.45%	77
2021 Q2	$978K	Buy	19,657 +943	+5%	+$45.3K	0.46%	76
2021 Q1	$835K	Buy	18,714 +925	+5%	+$42K	0.43%	79
2020 Q4	$818K	Sell	17,789 -5,229	-23%	-$240K	0.54%	72
2020 Q3	$1.08M	Sell	23,018 -698	-3%	-$35K	0.86%	41
2020 Q2	$1.21M	Buy	23,716 +516	+2%	+$26.5K	1%	31
2020 Q1	$1.1M	Buy	23,200 +1,327	+6%	+$70.8K	1.12%	25
2019 Q4	$1.28M	Buy	21,873 +283	+1%	+$15.7K	0.96%	31
2019 Q3	$1.15M	Buy	21,590 +684	+3%	+$35.2K	0.8%	37
2019 Q2	$1.05M	Buy	20,906 +873	+4%	+$43.8K	0.83%	41
2019 Q1	$1.05M	Buy	20,033 +2,091	+12%	+$104K	0.91%	33
2018 Q4	$857K	Buy	17,942 +1,607	+10%	+$79.1K	0.9%	38
2018 Q3	$820K	Buy	16,335 +2,268	+16%	+$115K	0.76%	46
2018 Q2	$709K	Buy	14,067 +557	+4%	+$28.1K	0.66%	60
2018 Q1	$660K	Buy	13,510 +3,103	+30%	+$145K	0.6%	63
2017 Q4	$461K	Buy	+10,407	New	+$481K	0.45%	87

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KCS Wealth Advisory's GSK Position: Q3 2023 in Review

KCS Wealth Advisory increased its GSK (GSK) stake by 1.5% in Q3 2023, buying an estimated $11.1K and bringing the position to 21,391 shares worth $775K. The position accounts for 0.33% of the portfolio, ranked #74.

KCS Wealth Advisory first reported a position in GSK in Q4 2017 and has held it in 24 quarters since. The position peaked at $1.28M in Q4 2019. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

KCS Wealth Advisory held 21,391 shares of GSK worth $775K as of Q3 2023.
KCS Wealth Advisory bought 314 GSK shares in Q3 2023, an estimated $11.1K.
GSK made up 0.33% of KCS Wealth Advisory's portfolio in Q3 2023, its #74 holding.
KCS Wealth Advisory first reported a position in GSK in Q4 2017 and has held it in 24 quarters since.
KCS Wealth Advisory's GSK position peaked at $1.28M in Q4 2019.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on KCS Wealth Advisory's 13F filing for Q3 2023, filed 3 Nov 2023.